Article info
Original research
Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy
- Correspondence to Mrs Yuka Aimono, Department of Pharmacy, Hitachi, Ltd., Hitachi General Hospital, Hitachi, Ibaraki, Japan; yuka.aimono.cp{at}hitachi.com
Citation
Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy
Publication history
- Received January 15, 2020
- Revised March 10, 2020
- Accepted March 17, 2020
- First published April 3, 2020.
Online issue publication
November 29, 2021
Article Versions
- Previous version (3 April 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.